What should I do if I become drug-resistant after taking Avatrombopag?

Avatrombopag (Avatrombopag) is a prescription drug used to help increase platelet counts in adults with chronic liver disease (CLD) and chronic immune thrombocytopenia (ITP), but is not used to normalize platelet counts in these patients. It is not known whether avatrombopag is safe and effective in children.

Avatrombopag effectively maintained platelet counts in patients with immune thrombocytopenia who were intolerant to tyrosine kinase inhibitor therapy. In clinical studies, avatrombopag may be used in combination with fostamatinib to enhance platelet responses and reduce the severity of fostamatinib-related adverse events while maintaining an adequate therapeutic response in chronic immune thrombocytopenia. Avatropopag 40 mg/day monotherapy is very effective in achieving and maintaining high platelet counts. However, everyone’s physique is different and their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for eligible patients. The price of a common specification of 20mg*15 tablets may be more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).